Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction

被引:292
作者
Schwandner, R [1 ]
Yamaguchi, K [1 ]
Cao, ZD [1 ]
机构
[1] Tularik Incorp, San Francisco, CA 94080 USA
关键词
cytokines; inflammation; signaling; kinases; transcription;
D O I
10.1084/jem.191.7.1233
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Signaling through its widely distributed cell surface receptor, interleukin (IL)-17 enhances the transcription of genes encoding proinflammatory molecules. Although it has been well documented that IL-17 activates the transcription factor nuclear factor (NF)-kappa B and c-Jun NH2-terminal kinase (JNK), the upstream signaling events are largely unknown. Here we report the requirement of tumor necrosis factor receptor-associated Factor (TRAF)6 in IL-17-induced NF-kappa B and JNK activation. In embryonic fibroblasts (EFs) derived from TRAF6 knockout mice, IL-17 failed to activate the I kappa D kinases (IKKs) and JNK. Consequently, IL-17-induced IL-6 and intracellular adhesion molecule 1 expression in the TRAF6-deficient cells was abolished. Lack of TRAF6 appeared to be the sole defect responsible for the observed failure to respond to IL-17, because transient transfection of TRAF6 expression plasmid into the TRAF6-deficient cells restored IL-17-induced NF-kappa B activation in a luciferase reporter assay. Furthermore, the levels of IL-17 receptor (IL-17R) on the TRAF6-deficient EFs were comparable to those on the wild-type control cells. Defect in IL-17 response was not observed in TRAF2-deficient EFs. Moreover, when TRAF6 and IL-17R were coexpressed in 293 cells, TRAF6 coimmunopercipitated with IL-17R. Together, these results indicate that TRAF6, but not TRAF2, is a crucial component in the IL-17 signaling pathway leading to proinflammatory responses.
引用
收藏
页码:1233 / 1239
页数:7
相关论文
共 50 条
[1]  
Aarvak T, 1999, SCAND J IMMUNOL, V50, P1
[2]   Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function [J].
Adachi, O ;
Kawai, T ;
Takeda, K ;
Matsumoto, M ;
Tsutsui, H ;
Sakagami, M ;
Nakanishi, K ;
Akira, S .
IMMUNITY, 1998, 9 (01) :143-150
[3]  
Aizawa S, 1997, J BIOL CHEM, V272, P2042
[4]  
Albanesi C, 1999, J IMMUNOL, V162, P494
[5]  
Antonysamy MA, 1999, J IMMUNOL, V162, P577
[6]   Evidence for a role of IL-17 in alloimmunity: A novel IL-17 antagonist promotes heart graft survival [J].
Antonysamy, MA ;
Fanslow, WC ;
Fu, F ;
Li, W ;
Qian, S ;
Troutt, AB ;
Thomson, AW .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) :93-93
[7]  
Awane M, 1999, J IMMUNOL, V162, P5337
[8]   NF-kappa B: Ten years after [J].
Baeuerle, PA ;
Baltimore, D .
CELL, 1996, 87 (01) :13-20
[9]  
BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
[10]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683